home / stock / prld / prld quote
Last: | $4.07 |
---|---|
Change Percent: | -0.25% |
Open: | $4.05 |
Close: | $4.07 |
High: | $4.07 |
Low: | $3.99 |
Volume: | 18,543 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.07 | $4.05 | $4.07 | $4.07 | $3.99 | 18,543 | 04-26-2024 |
$4.04 | $3.99 | $4.04 | $4.09 | $3.99 | 115,746 | 04-25-2024 |
$3.87 | $3.87 | $3.87 | $4.13 | $3.87 | 28,584 | 04-24-2024 |
$3.87 | $3.89 | $3.87 | $4.07 | $3.87 | 24,900 | 04-23-2024 |
$3.85 | $3.75 | $3.85 | $3.9643 | $3.75 | 50,051 | 04-22-2024 |
$3.72 | $3.45 | $3.72 | $3.86 | $3.45 | 57,910 | 04-19-2024 |
$3.44 | $4.16 | $3.44 | $4.18 | $3.42 | 112,889 | 04-18-2024 |
$4.18 | $4.8 | $4.18 | $4.98 | $4.1 | 68,937 | 04-17-2024 |
$4.91 | $5.63 | $4.91 | $5.63 | $4.79 | 38,381 | 04-16-2024 |
$5.63 | $5.75 | $5.63 | $5.83 | $5.4164 | 89,987 | 04-15-2024 |
$5.62 | $5.27 | $5.62 | $5.77 | $5.12 | 58,031 | 04-12-2024 |
$5.22 | $4.94 | $5.22 | $5.35 | $4.855 | 45,170 | 04-11-2024 |
$4.95 | $4.82 | $4.95 | $5.17 | $4.67 | 24,121 | 04-10-2024 |
$4.99 | $4.69 | $4.99 | $5.07 | $4.56 | 64,215 | 04-09-2024 |
$4.7 | $4.72 | $4.7 | $4.82 | $4.6 | 15,589 | 04-08-2024 |
$4.7 | $4.67 | $4.7 | $4.98 | $4.47 | 17,673 | 04-05-2024 |
$4.74 | $4.72 | $4.74 | $4.85 | $4.58 | 21,812 | 04-04-2024 |
$4.72 | $4.52 | $4.72 | $4.755 | $4.52 | 28,329 | 04-03-2024 |
$4.62 | $4.63 | $4.62 | $4.65 | $4.41 | 31,908 | 04-02-2024 |
$4.69 | $4.76 | $4.69 | $4.93 | $4.6101 | 14,441 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at ...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematolo...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology compan...